Table 1

Selected adopted cellular therapy trials in solid tumor malignancies

Type of therapyTargetPhaseClinical trial number
CAR TEGFRINCT03618381
CAR TB7H3; CD19INCT04483778
CAR THER2INCT03740256
CAR THER2INCT04660929
CAR TGlypican 3INCT02932956
CAR TPSCAI/IINCT02744287
CAR TROR1INCT02706392
CAR TMesothelinINCT03054298
CAR TTnMUC1INCT04025216
TILMelanoma; HNSCCINCT03991741
TILMelanoma; HNSCC; NSCLCIINCT03645928
TILOvarian cancer; pancreatic ductal adenocarcinoma; colorectal cancerIINCT03610490
TILOvarian cancer; anaplastic thyroid cancer; osteosarcomaIINCT03449108
TILSarcomaINCT04052334
TILCervical cancerIINCT03108495
TILVarious solid tumor cancersIINCT03935893
TCRMAGE A4/8INCT03247309
TCRVarious solid tumor cancers—neoantigen TCRsINCT03970382
TCRPreferentially expressed antigen in melanoma-positive tumorsINCT03686124
TCRMAGE A3/A6INCT03139370
TCRHPV16+ cancersINCT03912831
TCRMAGE A4+ HNSCCINCT04408898
TCRNY-ESO-1I/IINCT02650986
  • CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PSCA, prostate stem cell antigen; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte.